ELTX (Elicio Therapeutics) Interest Expense: $-1.36 Mil (TTM As of Mar. 2026)


ELTX Elicio Therapeutics Inc ELTX
32 GF Score
Price $3.26
! 1 Warning Sign
View Full Analysis

What is Elicio Therapeutics Interest Expense?

Elicio Therapeutics ELTX -37.35% 32 Interest Expense is $-1.36 Mil as of Mar. 2026. GuruFocus rates ELTX with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Elicio Therapeutics's interest expense for the three months ended in Mar. 2026 was $ -0.41 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.36 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Elicio Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -10.60 Mil. Elicio Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ -0.41 Mil. Elicio Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Elicio Therapeutics  (NAS:ELTX) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Elicio Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $-0.41 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-10.60 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $13.30 Mil.

Elicio Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Elicio Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Elicio Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Elicio Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicio Therapeutics Interest Expense Chart

Elicio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.88 -3.60 -1.06 -0.46 -1.13

Elicio Therapeutics Quarterly Data
Mar20 Dec20 Mar21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.19 -0.43 -0.34 -0.41
ELTX
32GF Score
Elicio Therapeutics Inc ELTX
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicio Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-1.36 Mil mean?
Elicio Therapeutics (ELTX) has a Interest Expense of $-1.36 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Elicio Therapeutics and its competitors.
Is Elicio Therapeutics' Interest Expense too high?
Elicio Therapeutics' current Interest Expense is $-1.36 Mil. Overall, Elicio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' Interest Expense compare to GOSS and GANX?
Elicio Therapeutics' Interest Expense of $-1.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Elicio Therapeutics and its competitors. Elicio Therapeutics's current Interest Expense is $-1.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current Interest Expense of $-1.36 Mil. The current Interest Expense is $-1.36 Mil. Elicio Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current Interest Expense is $-1.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicio Therapeutics Business Description

Other Exchanges 9HA:Germany
Address 451 D Street, Suite 501, 5th Floor, Boston, MA, USA, 02210
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
32GF Score

Get the complete analysis for ELTX

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.26
Price